AU2007231651A1 - Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors - Google Patents
Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors Download PDFInfo
- Publication number
- AU2007231651A1 AU2007231651A1 AU2007231651A AU2007231651A AU2007231651A1 AU 2007231651 A1 AU2007231651 A1 AU 2007231651A1 AU 2007231651 A AU2007231651 A AU 2007231651A AU 2007231651 A AU2007231651 A AU 2007231651A AU 2007231651 A1 AU2007231651 A1 AU 2007231651A1
- Authority
- AU
- Australia
- Prior art keywords
- use according
- defibrotide
- angiogenesis
- formulation
- dependent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
AUSTRALIA
Patents Act 1990 COMPLETE SPECIFICATION Standard Patent Applicant: Gentium SPA Invention Title: DEFIBROTIDE AND/OR OLIGODEOXYRIBONUCLEOTIDES FOR TREATING ANGIOGENESIS-DEPENDENT TUMORS The following statement is a full description of this invention, including the best method for performing it known to me/us: SFormulations with anti-angiogenesis-dependent tumour 0 action The subject of the present invention is a method for treating a tumor-affected mammalian by administering to said mammalian an effective amount of defibrotide ND and/or oligotide; in particular it relates to the use of oligotide and/or defibrotide for the treatment of angiogenesis-dependent tumors.
0 Background of the invention Angiogenesis is a multi-step process leading to the formation of new blood vessels from pre-existing vasculature and it is necessary for primary tumor growth, invasiveness and development of metastases It is normally suppressed in the adult, where angiogenesis occurs transiently only during reproduction, development and wound healing. Beyond a critical volume, a tumor cannot expand further in the absence of neovascularization To promote this, a tumor must acquire the angiogenic phenotype which is the result of the net balance between positive (proangiogenic) and negative (anti-angiogenic) regulators However, tumors are highly heterogenous in vascular architecture, differentiation, and functional blood supply These differences in size of avascular preangiogenic tumors may be due in part to the capacity of tumor cells to survive under differing degrees of hypoxia (18).
Evidence for the angiogenesis-dependency of certain tumors, such as multiple myeloma, even non-solid leukemias and lymphomas and as well as breast colorectal gastric prostate cervix hepatocellular and non-small cell lung cancer (13) came from the observation that the measure of the degree of angiogenesis, the microvessel density, is an independent prognostic factor for survival in the mentioned clinical entities In a recent clinical study, again in breast carcinoma, it became clear that angiogenesis-related genes are important for clinical outcome, for example the vascular endothelial cell growth factor VEGF, the VEGF receptor FLT1, and metalloproteinase MMP9 Definitions The term oligotide is herein used to identify any oligodeoxyribonucleotide having a molecular weight of 4000-10000 Dalton. Preferably it identifies any oligodeoxyribonucleotide having the following analytical parameters: molecular weight 4000-10000 Dalton, hyperchromicity A+T/C+G: 1.100-1.455, A+G/C+T: 0.800-1.160, specific rotation: +46.80, preferably +46.20.
The oligotide may be produced by extraction from animal and/or vegetable tissues, in particular, from mammalian organs, or may be produced synthetically. Preferably, when produced by extraction, it will be obtained in accordance with the method described in and which are incorporated herein by reference. The oligotide is known to be endowed with a significant anti-ischemic activity.
The term defibrotide identifies a polydeoxyribonucleotide that is obtained by extraction from animal and/or vegetable tissues but which may also Sbe be produced synthetically; the polydesoxyriboo nucleotide is normally used in the form of an alkalim metal salt, generally a sodium salt, and generally has a molecular weight of about 45-50 kDa (CAS Registry Number: 83712-60-1). Preferably, defibrotide presents V) the physical/chemical characteristics described in (4) and which are incorporated herein by reference.
C< DESCRIPTION OF THE INVENTION We have recently developed a model for an alternative C( pathway of tumor angiogenesis. In addition to the endothelial cell sprouting from pre-existing vessels, we suggest that blood borne endothelial cells might also give rise to the tumor vasculature. These endothelial-like cells (ELC) can transdifferentiate from tumor-associated dendritic cells under specific culture conditions Briefly, monocytes are elutriated from leukapheresis products of healthy human blood donors and cultured in the presence of granulocyte-macrophage-colony stimulating factor (GM- CSF) and interleukin 4 (IL-4) to stimulate the differentiation of dendritic cells (DC) In addition, cells are treated with a cocktail specifically released by tumor cells (M-CSF, IL.6 and lactate, Gottfried et al., manucript submitted) to promote the outgrowth of tumor-associated dendritic cells (TuDC).
These TuDC-ELC acquire the phenotype of endothelial cells (FactorVIII related Ag, vWF) while they lose monocytic (CD14) and dendritic cell markers (CDla).
Importantly, they do not express CD34, nor CD133 or CD146 which proves that they are real transdifferentiation products and no contaminants of either circulating endothelial progenitors (CD34, CD133) or mature circulating endothelial cells (CD146).
In addition, they are able to form tube-like structures O in MatrigelTM, an in vitro assay of angiogenesis.
Cg The MatrigelTM assay is one of the most popular and widely used in vitro angiogenesis assays (22).
MatrigelTM is a semisolid synthetic mixture of extracellular matrix proteins which simulate the matrix c that physiologically exist beneath the endothelial cell wall of a blood vessel. When the cells of question are Sseeded onto this matrix in microscopic chamber slides, C1 they are activated to form tubular structures in 3-7 days, but only in the case that they have an endothelial phenotype. Therefore, this assay is suitable to show the potential capacity of cells to give rise to a tumor vasculature.
Our data data demonstrate that oligotide and/or defibrotide in clinical and subclinical concentrations can inhibit tube formation of transdifferentiating
ELC
(TuDC-ELC) in MatrigelTM. TuDC-ELC and mature, differentiated endothelial cells, [human umbilical vene (HUVEC) or microvascular endothelial cells (HMEC) as "stable" controls] were incubated in the presence or absence of oligotide or Defibrotide (lOpg/mL each) for 7 days. Importantly, after a single addition of Defibrotide, HUVEC and HMEC are not affected in their tube formation potential, suggesting that Defibrotide and/or oligotide only target transdifferentiating endothelial cells (Figure 1 However, when Defibrotide was added repeatedly, it could also block angiogenesis of mature, fully differentiated endothelial cells (see below).
By the help of a complimentary software from the NIH (Image J, http://rsb.info.nih.gov/ij/), we are able to quantify these effects, the total length of tubes and the area of the photograph are assessed, the O microvascular density (MVD) is then given in total in length/area [pix-l]. DF significantly (p=0.02, TTEST) downregulates MVD of TuDC-ELC (Figure 1 B).
To support these data with an alternative angiogenesis assay the sprouting of rat aorta endothelial cells in MatrigelTM was prevented by nearly 100%, when DF was applied on a daily basis (Figure suggesting that DF O not only acts on transdifferentiating, but also on rC mature, fully differentiated endothelial cells.
The aortic ring assay investigates macrovascular endothelial cells. But often, the tumor vasculature consists of microvascular endothelial cells. Therefore, a third in vitro angiogenesis assay was performed on the basis of microvascular endothelial cells vascularizing through a layer of dermal fibroblasts after 9-11 days of culture. These vessel-like structures can subsequently be visualized by staining for CD31 and vWF.
As demonstrated in Figure 3 (A and DF can also block angiogenesis of human microvascular endothelial cells with a superiority for the daily application.
Interestingly, concentrations around 10 pg/mL appear to be the most effective. A single application of DF could not significantly block angiogenesis.
Taken together, our data strongly suggest that defibrotide and/or oligotide can block angiogenesis of tumor-associated transdifferentiating endothelial cells and those that arise from already existing vascular cells.
It is subject to ongoing studies whether oligotide and defibrotide also inhibit angiogenesis in vivo. We are currently performing a dorsal skin chamber assay (14) that investigates the effect of defibrotide in a highly O vascularized human gastric carcinoma mouse model (Xenograft system). First data clearly show that the microvascular density (MVD) of DF-treated tumors is lower than that of control tumors. This set of n experiments will be reproduced in due time.
The mechanism of action by which DF can block Sangiogenesis remains to be elucidated, but preliminary evidence from Western Blot analyses suggest a C downregulating effect of DF on activated p70S6 kinase (p-p70S6), a mitogen-activated protein kinase.
Additional evidence for the impact of p70S6 kinase was obtained from another tube formation assay with HMEC incubated in the presence or absence of the p70S6 kinase inhibtor DRB.
There are also first clinical data available for patients (pts.) having received allogeneic stem cell transplantation (SCT): In a cohort of 17 defibrotidetreated pts a striking decline in serum VEGF levels has been seen, also suggesting that defibrotide might act through growth factor withdrawal for sprouting tumor endothelial cells.
Defibrotide and oligotide are strong candidates for a therapy of angiogenesis-dependent tumors and might be used alone or in combination with other antiangiogeneic agents, such as rapamycin (14).
Interestingly, rapamycin has the negative side effect of pro-thrombotic activity (15) that could be attenuated by the simultaneous application of the antithrombotic and fibrionolytic defibrotide.
References 1. US5646127 S2. US5646268 0 3. US6046172 C- 4. US4985552 US5223609 6. 't Veer,L.J., et al.(2002) Gene expression profiling predicts clinical outcome of breast cI1 cancer. Nature, 415, 530-536.
7. Abdalla,S.A., et al.(1999) Prognostic relevance of microvessel density in colorectal tumours.
Oncol.Rep., 6, 839-842.
8. Andersen,N.F., et al. (2005) Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br.J.Haematol., 128, 210-217.
9. Bostwick,D.G. Iczkowski,K.A. (1998) Microvessel density in prostate cancer: prognostic and therapeutic utility. Semin.Urol.Oncol., 16, 118- 123.
Eissner,G., et al. (2002) Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. Blood, 100, 334-340.
11. Fernandez,P.B., et al. (2001) Dendritic cells derived from peripheral monocytes express endothelial markers and in the presence of angiogenic growth factors differentiate into endothelial-like cells. Eur.J.Cell Biol., 80, 99- 110.
12. Folkman,J., et al. (1971) Isolation of a tumor factor responsible for angiogenesis. J.Exp.Med., 133, 275-288.
13. Fontanini,G., et al. (1995) Microvessel count O predicts metastatic disease and survival in nonlV) small cell lung cancer. J.Pathol., 177, 57-63.
14. Guba,M., et al.(2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.
SNat.Med., 8, 128-135.
(N
C 15. Guba,M., et al. (2005) Rapamycin induces tumor- 0 specific thrombosis via tissue factor in the presence of VEGF. Blood.
16. Hanahan,D. Folkman,J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86, 353-364.
17. Hasan,J., et al. (2002) Intra-tumoural microvessel density in human solid tumours. Br.J.Cancer, 86, 1566-1577.
18. Helmlinger,G., et al. (1997) Interstitial pH and p02 gradients in solid tumors in vivo: highresolution measurements reveal a lack of correlation. Nat.Med., 3, 177-182.
19. Kainz,C., et al. (1995) Prognostic value of tumour microvessel density in cancer of the uterine cervix stage IB to IIB. Anticancer Res., 15, 1549-1551.
Morabito,A., et al. (2004) Antiangiogenic strategies, compounds, and early clinical results in breast cancer. Crit Rev.Oncol.Hematol., 49, 91- 107.
21. Podar,K. Anderson,K.C. (2005) The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood, 105, 1383-1395.
22. Staton,C.A., et al. (2004) Current methods for o assaying angiogenesis in vitro and in vivo.
l^ Int.J.Exp.Pathol., 85, 233-248.
23. Sun,H.C., et al. (1999) Microvessel density of hepatocellular carcinoma: its relationship with Sprognosis. J.Cancer Res.Clin.Oncol., 125, 419-426.
S24. Verheul,H.M., et al. (2004) Are tumours Sangiogenesis-dependent? J.Pathol., 202, 5-13.
D 25. Weidner,N., et al. (1992) Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J.Natl.Cancer Inst., 84, 1875-1887.
26. Xiangming,C., et al. (1998) Angiogenesis as an unfavorable factor related to lymph node metastasis in early gastric cancer. Ann.Surg.Oncol., 5, 585- 589.
It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country.
In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.
Claims (29)
1. Use of defibrotide and/or oligodeoxyribonucleotides having a molecular weight of 4000-10000 Dalton, for the l) manufacture of a pharmaceutical formulation for the NO treatment of angiogenesis-dependent tumor. c(
2. Use according to claim 1, characterized in that said O oligodeoxyribonucleotides have the following analytical (CN parameters: h <10, A+T/C+G: 1.100-1.455, A+G/C+T: 0.800-1.160, specific rotation: +300- +46.80.
3. Use according to claim 2, characterized in that the specific rotation is comprised between +300 and +46.20.
4. Use according to claim 1, characterized in that said oligodeoxyribonucleotides and/or defibrotide are obtained by extraction from animal and/or vegetable tissues, preferaby from mammalian organs.
Use according to claim 1, characterized in that said oligodeoxyribonucleotides and/or defibrotide are obtained synthetically.
6. Use according to claim 1, characterized in that said angiogenesis-dependent tumor is multiple myeloma.
7. Use according to claim 1, characterized in that said angiogenesis-dependent tumor is breast carcinoma.
8. Use according to claim 1, characterized in that said formulation is administered to a mammalian.
9. Use according to claim 1, characterized in that said mammalian is a human.
Use according to claim 1, characterized in that said formulation is administered intravenously. o
11. Use according to claim 1, characterized in that 0 said formulation is an aqueous solution. CI
12. Use according to claim 1, characterized in that said formulation contains at least another active ingredient with anti-tumour action. IO
13. Use according to claim 12, characterized in that the other active ingredient with anti-tumour action is selected from rapamycin, paclitaxel, monocrotaline, SBCNU, and/or cyclophosphamide.
14. Use according to claim 1, characterized in that said formulation contains customary excipients and/or adjuvants.
Use of defibrotide and/or an oligodeoxyribonucleotide C having a molecular weight of 4000-10000 Dalton in combination Swith rapamycin for the manufacture of a pharmaceutical formulation for the treatment of angiogenesis-dependent tumour.
16. A method for the treatment of angiogenesis-dependent In \O tumour, the method comprising administering a pharmaceutical formulation comprising defibrotide and/or an oligodeoxyribonucleotide having a molecular weight of 4000- 10000 Dalton, in combination with rapamycin.
17. Use according to claim 15 or a method according to claim 16, characterized in that said oligodeoxyribonucleotide has the following analytical parameters: h <10, A+T/C+G: 1.100-1.455, A+G/C+T: 0.800-1.160, specific rotation: +300- +46.80.
18. Use or method according to claim 17, characterized in that the specific rotation is comprised between +300 and +46.20.
19. Use according to claim 15 or a method according to claim 16, characterized in that said oligodeoxyribonucleotide and/or defibrotide are obtained by extraction from animal and/or vegetable tissues.
Use according to claim 15 or a method according to claim 16, characterized in that said oligodeoxyribonucleotide and/or defibrotide are obtained by extraction from mammalian organs.
21. Use according to claim 15 or a method according to claim 16, characterized in that said oligodeoxyribonucleotide and/or defibrotide are obtained synthetically.
S22. Use according to claim 15 or a method according to C claim 16, characterized in that said angiogenesis-dependent O tumor is multiple myeloma. 0 f
23. Use according to claim 15 or a method according to claim 16, characterized in that said angiogenesis-dependent tumour is breast carcinoma. IN \O
24. Use according to claim 15 or a method according to claim 16, characterized in that said formulation is administered to a mammalian.
25. Use according to claim 15 or a method according to claim 16, characterized in that said formulation is administered to a human.
26. Use according to claim 15 or a method according to claim 16, characterized in that said formulation is is administered intravenously.
27. Use according to claim 15 or a method according to claim 16, characterized in that said formulation is an aqueous solution.
28. Use according to claim 15 or a method according to claim 16, characterized in that said formulation contains customary excipients and/or adjuvants.
29. Use according to claim 15 or a method according to claim 16, substantially as herein described with reference to any one of the accompanying drawings.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2007231651A AU2007231651B2 (en) | 2005-03-03 | 2007-10-25 | Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI2005A000336 | 2005-03-03 | ||
US60/731,404 | 2005-10-28 | ||
AU2006222044A AU2006222044A1 (en) | 2005-03-03 | 2006-02-27 | Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors |
AU2007231651A AU2007231651B2 (en) | 2005-03-03 | 2007-10-25 | Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2006222044A Division AU2006222044A1 (en) | 2005-03-03 | 2006-02-27 | Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2007231651A1 true AU2007231651A1 (en) | 2007-11-15 |
AU2007231651B2 AU2007231651B2 (en) | 2011-09-15 |
Family
ID=39410435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2007231651A Ceased AU2007231651B2 (en) | 2005-03-03 | 2007-10-25 | Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2007231651B2 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1202750A4 (en) * | 1997-04-28 | 2002-10-16 | Arsinur Burcoglu | Method of treating hiv infection and related secondary infections thereof |
DE19740384A1 (en) * | 1997-09-08 | 1999-03-11 | Max Delbrueck Centrum | Antisense oligonucleotides specific for protein kinase C isoforms |
-
2007
- 2007-10-25 AU AU2007231651A patent/AU2007231651B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU2007231651B2 (en) | 2011-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2006222045B2 (en) | Oligodeoxyribonucleotides of 4000-10000 Dalton for treating tumors | |
Liu et al. | A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes | |
Liu et al. | G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice | |
Hasenstein et al. | Efficacy of Tie2 receptor antagonism in angiosarcoma | |
Yan et al. | Decreasing CNPY2 expression diminishes colorectal tumor growth and development through activation of p53 pathway | |
WO2011128115A1 (en) | Analogues of etoposide for the treatment of tumours | |
Wufuer et al. | Downregulation of Rac1/PAK1/LIMK1/cofilin signaling pathway in colon cancer SW620 cells treated with Chlorin e6 photodynamic therapy | |
CN101827601A (en) | Anti-cancer composition comprising microRNA molecules | |
Chen et al. | Pharmacological and cell-specific genetic PI3Kα inhibition worsens cardiac remodeling after myocardial infarction | |
AU2007231651B2 (en) | Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors | |
EP1867335B1 (en) | Oligodeoxyribonucleotides combined with rapamycin for treating cancer | |
KR101853731B1 (en) | Composition for inducing cell senescence comprising Linc-ASEN gene expression inhibitor | |
CN108653297B (en) | Application of ganodermanondiol with cell nucleus cathepsin L as target in pharmacy | |
Kim et al. | CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells | |
KR20050007455A (en) | Method to inhibit cell growth using oligonucleotides | |
Wu et al. | Ergosta-7, 22-diene-2β, 3α, 9α-triol (EGDT) from Ganoderma lucidum inhibits nasopharyngeal carcinoma cells by blocking EGFR signaling pathway | |
CN101333237B (en) | Oligonucleotide with breast carcinoma treating function | |
Zhu et al. | CXC motif chemokine receptor type 4 disrupts blood-brain barrier and promotes brain metastasis through activation of the PI3K/AKT pathway in lung cancer | |
WU et al. | Expression autophagy-related gene pULK and PI3KC3 and their correlation with human non-small-cell carcinoma | |
Deutsch et al. | Radiotherapy for localized rectal cancer | |
Türkeri et al. | Intravesical chemotherapy | |
Σίσιου | Plasma extracellular vesicles as tools for early detection of lung cancer | |
Hsia et al. | P2-123: Induction of apoptosis by rhein via reactive oxygen species production, GADD153 expression, and caspase-3 activation in human lung cancer A-549 cells | |
Jagadeeswaran et al. | P2-124: Focal adhesion paxillin induces nodular cell growth, invasion, and angiogenesis in lung cancer | |
TW201204369A (en) | Pharmaceutical composition for inhibiting proliferation and metastasis of colorectal cancer and metrocarcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |